77661-80-4

Usage

Uses

Used in Organic Synthesis:
2-(2-(benzyloxy)ethyl)propane-1,3-diol is used as a key intermediate for the synthesis of various organic compounds. Its unique structure allows it to be a versatile building block in the creation of complex molecules, which is essential in both academic research and industrial applications.
Used in Chemical Production:
In the chemical industry, 2-(2-(benzyloxy)ethyl)propane-1,3-diol is used as a raw material for the production of different chemicals. Its reactivity and ability to form stable bonds with other molecules make it a valuable component in the synthesis of a wide range of chemical products.
Used in Academic Research:
2-(2-(benzyloxy)ethyl)propane-1,3-diol is used as a research tool in academic settings to explore new chemical reactions and pathways. Its unique properties and reactivity provide opportunities for scientists to investigate novel chemical processes and develop new methodologies in organic chemistry.
Used in Industrial Applications:
In industrial applications, 2-(2-(benzyloxy)ethyl)propane-1,3-diol is used as a component in the manufacturing process of various products. Its role in the synthesis of complex molecules contributes to the development of new materials and compounds that have potential applications in various industries.

Upstream product

• 41478-45-9 Diethyl<(2-benzyloxy)ethyl>malonate 
• 113522-59-1 CH(CH₂CH₂OBn)(CO₂Me)2 
• 936-51-6 2-phenyl-1,3-dioxolane 
• 1462-37-9 bromoethyl-2-benzyl ether 
• 58841-52-4 2-(benzyloxy)ethyl methanesulfonate 
• 54555-84-9 benzyl iodoethyl ether 
• 622-08-2 2-Benzyloxyethanol 

Downstream Products

• 136883-95-9 4-Benzyloxy-2-(tert-butyl-dimethyl-silanyloxymethyl)-butan-1-ol 
• 77661-81-5 (4-Benzyloxy-2-methoxycarbonylmethoxymethyl-butoxy)-acetic acid methyl ester 
• 213273-33-7 5-(2-benzyloxyethyl)-1,3-dioxan-2-one 
• 569678-80-4 toluene-4-sulfonic acid 4-benzyloxy-2-hydroxymethyl-butyl ester 
• 113522-73-9 4-(5,5-Dimethyl-6-oxo-cyclohex-1-enylmethyl)-dihydro-furan-2-one 
• 113522-70-6 4-(5,5-Dimethyl-6-oxo-cyclohex-1-enyl)-3-hydroxymethyl-butyric acid 
• 113522-82-0 4-(5,5-Dimethyl-6-oxo-cyclohex-1-enyl)-3-formyl-butyric acid methyl ester 
• 113522-71-7 4-(5,5-Dimethyl-6-oxo-cyclohex-1-enyl)-3-hydroxymethyl-butyric acid methyl ester 
• 113522-61-5 (4-Benzyloxy-2-iodomethyl-butoxy)-tert-butyl-diphenyl-silane 
• 113522-65-9 2-[2-(tert-Butyl-diphenyl-silanyloxymethyl)-4-hydroxy-butyl]-6,6-dimethyl-cyclohex-2-enone 
• 113522-69-3 4-(tert-Butyl-diphenyl-silanyloxy)-3-(5,5-dimethyl-6-oxo-cyclohex-1-enylmethyl)-butyric acid 
• 113522-72-8 4-(tert-Butyl-diphenyl-silanyloxy)-3-(5,5-dimethyl-6-oxo-cyclohex-1-enylmethyl)-butyric acid methyl ester 
• 113522-63-7 2-[4-Benzyloxy-2-(tert-butyl-diphenyl-silanyloxymethyl)-butyl]-6,6-dimethyl-cyclohex-3-enone 
• 113522-64-8 2-[4-Benzyloxy-2-(tert-butyl-diphenyl-silanyloxymethyl)-butyl]-6,6-dimethyl-cyclohex-2-enone 

Relevant academic research and scientific papers

NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME

A compound selectively inhibiting Nav1.7 over Nav1.5 is provided. A heteroaromatic amide derivative or salt thereof showing high efficacy for various diseases associated with Nav1.7 such as pain, represented by the general formula (I) [wherein, X1-X2 is N-C or C-N, Y1 , Y2, Y3 and Y4 are -CH2-, -CR4aH- or -O- and so on, Z1 is-O- and so on, ring A is a 3- to 7-membered monocyclic aromatic ring and so on, R1a and R1b are a hydrogen atom or a halogen atom and so on, R2 is a hydrogen atom and so on, R3a, R3b and R3c are a hydrogen atom or an optionally substituted C1-C6 haloalkyl group and so on, R4a, R4b and R4c are, an optionally substituted C1-C6 haloalkyl group or C1-C6 haloalkoxy group and so on, R5a is a hydrogen atom and so on, R5a and R5b together form -CH2O- and so on, R6a and R6b are a hydrogen atom and so on, n is 1 or 2.].

NOVEL PHARMACEUTICAL COMPRISING HETEROAROMATIC AMIDE DERIVATIVE OR SALT THEREOF

PROBLEM TO BE SOLVED: To provide a compound useful for treating or preventing disease associated with voltage-dependent sodium channel (Nav1.7) such as disease involving a pain, disease involving an itch, autonomic nerve-associated disease, or a pharmaceutical composition thereof. SOLUTION: The present disclosure provides a compound illustrated by the following formula, and a pharmaceutical composition containing the same. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

Compound, liquid crystal composition, liquid crystal display element and liquid crystal display

The present invention relates to a compound, a liquid crystal composition, a liquid crystal display element, and a liquid crystal display. The compound is a compound represented by a formula I shown in the description. The liquid crystal composition of the present invention contains the compound represented by the formula I. The compound represented by the formula I has the advantages of good mutual solubility with other compounds and good UV resistance. As a reactive mesogen (RM), the compound has the advantages of good mutual solubility, high polymerization activity (less monomer residue), and strong binding ability. The compound can not only be used as a self-aligning agent for the liquid crystal compositions alone, but also can be used as a vertical alignment material for copolymerization with other RMs so as to be used as a self-aligning agent for the liquid crystal compositions in a PSA (polymer-supported alignment) and PS (polymer-stabilized) mode, the PI preparation process canbe avoided, the preparation process of the liquid crystal display element or liquid crystal display can be simplified, and the production efficiency can be improved.

Compounds, liquid crystal composition, liquid crystal display element and liquid crystal display

The invention relates to compounds, a liquid crystal composition, a liquid crystal display element and a liquid crystal display. The compounds are represented by a formula I shown in the description.The liquid crystal composition provided by the invention

LIQUID CRYSTAL MIXTURE AND LIQUID CRYSTAL DISPLAY

The invention relates to a compound of formula (I), wherein R11, R21, A11, A, Z, X11, X21, Y11, Y12, Sp11, Sp21, o and p have one of the meanings as given in claim 1. The invention further relates to method of production of a compound of formula (I), to the use of said compounds in LC media and to LC media comprising one or more compounds of formula (I). Further, the invention relates to a method of production of such LC media, to the use of such media in LC devices, and to LC device comprising a LC medium according to the present invention.The present invention further relates to a process for the fabrication such liquid crystal display and to the use of the liquid crystal mixtures according to the invention for the fabrication of such liquid crystal display.

METHOD OF CONTROLLING LACTATE PRODUCTION WITH PIPERDINE-DIONE DERIVATIVES

The invention provides novel compounds having the general formula: and tautomers and pharmaceutically acceptable salts thereof, wherein A1, A2, A3, A4, R1, R4, R5, R6, R7 and R8 are as defined herein, compositions including the compounds and methods of using the compounds.

PIPERIDINE-DIONE DERIVATIVES

The invention provides novel compounds having the general formula (I) and tautomers and pharmaceutically acceptable salts thereof, wherein A1, A2, A3, A4, R1, R4, R5, R6, R7 and R8 are as defined herein, compositions including the compounds and methods of using the compounds.

NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR

The present invention relates to indole derivatives useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said com- pounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.

Bivalent inhibitors for disrupting protein surface-substrate interactions and for dual inhibition of protein prenyltransferases

Low-molecular-weight compounds that disrupt protein-protein interactions (PPIs) have tremendous potential applications as clinical agents and as chemical probes for investigating intracellular PPI networks. However, disrupting PPIs is extremely difficult due to the large, flat interfaces of many proteins, which often lack structurally defined cavities to which drug-like molecules could bind in a thermodynamically favorable manner. Here, we describe a series of bivalent compounds that anchor to the enzyme active site to deliver a minimally sized surface-binding module to the targeted surface involved in transient PPI with a substrate. These compounds are capable of significantly inhibiting enzymatic reactions involving protein surface-substrate interaction in the single-digit nanomole range. Inhibitors of farnesyltransferase (FTase), which possesses a negatively charged local area on its α-subunit, were designed by attaching a module derived from a branched monoamine-containing gallate to a conventional active-site-directed CVTM tetrapeptide using an alkyl spacer. A significant improvement in inhibitory activity (>200-fold) against farnesylation of the K-Ras4B peptide was observed when the gallate module was attached to the CVTM tetrapeptide. Furthermore, the bivalent compounds had submicromolar inhibitory activity against geranylgeranylation of the K-Ras4B peptide catalyzed by GGTase I, which has an a-subunit identical to that of FTase. The anchoring strategy we describe would be useful for designing a new class of PPI inhibitors as well as dual enzyme inhibitors targeting common surface structures.